Durable Responses to Trastuzumab Deruxtecan in Patients with Leptomeningeal Metastases from Breast Cancer with Variable HER2 Expression

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Jul 29

PMID 39073687

Authors

David Rogawski

Toni Cao

Qian Ma

Meaghan Roy-OReilly

Lilian Yao

Nova Xu

Seema Nagpal

Affiliations

Soon will be listed here.

Abstract

Purpose: Emerging data suggest that trastuzumab deruxtecan (T-DXd) is an active treatment for brain metastases from HER2 + breast cancer. We aimed to characterize the activity of T-DXd in the treatment of leptomeningeal metastases (LM) from a range of HER2-altered cancers.

Methods: We reviewed neuro-oncology clinic records between July 2020 and December 2023 to identify patients who received T-DXd to treat LM.

Results: Of 18 patients identified, 6 had HER2 + breast cancer, 8 had HER2-low/negative breast cancer, 2 had HER2 + gastroesophageal cancer, and 2 had HER2-mutant non-small cell lung cancer (NSCLC). 10/18 (56%) patients had cytologically confirmed LM by CSF cytology or circulating tumor cell (CTC) capture. A partial response (PR) on MRI using the EORTC/RANO-LM Revised-Scorecard occurred in 4/6 (67%) patients with HER2 + breast LM, 2/8 (25%) patients with HER2-low/negative breast cancer, and 0/4 (0%) patients with HER2 + gastroesophageal cancer or HER2-mutant NSCLC. Median overall survival after initiating T-DXd was 5.8 months. Survival after initiating T-DXd was numerically longer for HER2 + breast cancer patients compared with HER2-low/negative breast and HER2-altered non-breast cancer patients (13.9 months vs. 5.2 months and 4.6 months, respectively). Landmark analysis showed that patients with radiologic LM response to T-DXd by 2.5 months had longer survival than non-responders (14.2 months vs. 2.6 months, HR 0.18, 95% CI 0.05-0.63, p < 0.05), and landmark analyses at 3.5 and 4.5 months after starting T-DXd showed a similar but nonsignificant trend.

Conclusion: T-DXd induces LM responses in a subset of patients, and such responses may be associated with prolongation of survival. Prospective trials are needed to clarify the role of T-DXd in treating LM and which patients are most likely to benefit.

Citing Articles

Metastatic brain tumors: from development to cutting-edge treatment.

Tanzhu G, Chen L, Ning J, Xue W, Wang C, Xiao G MedComm (2020). 2024; 6(1):e70020.

PMID: 39712454 PMC: 11661909. DOI: 10.1002/mco2.70020.

References

Roy-OReilly M, Lanman T, Ruiz A, Rogawski D, Stocksdale B, Nagpal S . Diagnostic and Therapeutic Updates in Leptomeningeal Disease. Curr Oncol Rep. 2023; 25(8):937-950. PMC: 10326117. DOI: 10.1007/s11912-023-01432-2. View

Ahn M, Chiu C, Cheng Y, Han J, Goldberg S, Greystoke A . Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. J Thorac Oncol. 2019; 15(4):637-648. DOI: 10.1016/j.jtho.2019.12.113. View

Gainor J, Sherman C, Willoughby K, Logan J, Kennedy E, Brastianos P . Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2014; 10(2):232-6. PMC: 4304931. DOI: 10.1097/JTO.0000000000000455. View

Gainor J, Chi A, Logan J, Hu R, Oh K, Brastianos P . Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol. 2016; 11(2):256-60. PMC: 4743545. DOI: 10.1016/j.jtho.2015.10.010. View

Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z . Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. Thorac Cancer. 2019; 11(1):176-180. PMC: 6938764. DOI: 10.1111/1759-7714.13259. View

Gaye E, Geier M, Bore P, Guilloique M, Lucia F, Quere G . Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung Cancer. 2019; 133:1-3. DOI: 10.1016/j.lungcan.2019.04.013. View

Andre F, Park Y, Kim S, Takano T, Im S, Borges G . Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 401(10390):1773-1785. DOI: 10.1016/S0140-6736(23)00725-0. View

Cortes J, Kim S, Chung W, Im S, Park Y, Hegg R . Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022; 386(12):1143-1154. DOI: 10.1056/NEJMoa2115022. View

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E . Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022; 387(1):9-20. PMC: 10561652. DOI: 10.1056/NEJMoa2203690. View

10.

Perez-Garcia J, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo J, de la Haba-Rodriguez J . Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 2022; 25(1):157-166. PMC: 9825345. DOI: 10.1093/neuonc/noac144. View

11.

Bartsch R, Berghoff A, Furtner J, Marhold M, Bergen E, Roider-Schur S . Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022; 28(9):1840-1847. PMC: 9499862. DOI: 10.1038/s41591-022-01935-8. View

12.

Alder L, Trapani D, Bradbury C, Van Swearingen A, Tolaney S, Khasraw M . Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ Breast Cancer. 2023; 9(1):19. PMC: 10063529. DOI: 10.1038/s41523-023-00519-0. View

13.

Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M . Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer. 2023; 9(1):82. PMC: 10567705. DOI: 10.1038/s41523-023-00584-5. View

14.

Mayer J, Pham T, Wong K, Scoggin J, Sales E, Clarin T . FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform. Cancer Genet. 2011; 204(11):589-95. DOI: 10.1016/j.cancergen.2011.10.011. View

15.

Le Rhun E, Devos P, Winklhofer S, Lmalem H, Brandsma D, Kumthekar P . Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. Neuro Oncol. 2022; 24(10):1726-1735. PMC: 9527515. DOI: 10.1093/neuonc/noac043. View

16.

Lebow E, Pike L, Seidman A, Moss N, Beal K, Yu Y . Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases. JAMA Oncol. 2023; 9(12):1729-1733. PMC: 10603573. DOI: 10.1001/jamaoncol.2023.4492. View

17.

Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D . Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer. 2017; 118(1):32-37. PMC: 5765232. DOI: 10.1038/bjc.2017.394. View

18.

Xing L, Pan Y, Shi Y, Shu Y, Feng J, Li W . Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clin Cancer Res. 2020; 26(23):6168-6175. DOI: 10.1158/1078-0432.CCR-20-2081. View

19.

Stemmler H, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V . Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2006; 18(1):23-8. DOI: 10.1097/01.cad.0000236313.50833.ee. View

20.

Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y . Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29(8):2110-2120. PMC: 10427426. DOI: 10.1038/s41591-023-02478-2. View